| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Total operating expenses | 5,879 | 2,928 | 5,255 | |
| Operating loss | -4,482 | -1,538 | -3,799 | |
| Fair value loss on warrant liability | - | - | -960 | |
| Warrant issuance costs | - | - | 54 | |
| Interest expense | - | - | 61 | |
| Interest income | 59 | 27 | 80 | |
| Financing expenses | - | -150 | - | |
| Change in fair value of derivative instruments | - | -6,512 | - | |
| Total other income (expense) | 59 | 6,689 | 925 | |
| Net loss | -4,423 | 5,151 | -2,874 | |
| Earnings per share basic | -0.04 | 0.02 | -0.37 | |
| Earnings per share diluted | -0.04 | -0.01 | -0.37 | |
| Weighted average number of diluted shares outstanding | 107,428,969 | 209,154,994 | 7,855,763 | |
| Weighted average number of shares outstanding basic | 107,428,969 | 48,388,862 | 7,855,763 | |
PLUS THERAPEUTICS, INC. (PSTV)
PLUS THERAPEUTICS, INC. (PSTV)